PROSPECTUS SUPPLEMENT
(To Prospectus dated January 2, 2018)
![LOGO](https://capedge.com/proxy/424B5/0001193125-18-216268/g691817g53s99.jpg)
5,000,000 Shares
6.75% Mandatory Convertible Preferred Stock, Series B
We are offering 5,000,000 shares of our 6.75% Mandatory Convertible Preferred Stock, Series B (“Series B Mandatory Convertible Preferred Stock”).
Dividends on the Series B Mandatory Convertible Preferred Stock will be payable on a cumulative basis when, as and if declared by our board of directors at an annual rate of 6.75% on the liquidation preference of $100.00 per share. We may pay declared dividends in cash or, subject to certain limitations, in shares of our common stock, no par value, or by delivery, at our election, of any combination of cash and shares of our common stock on January 15, April 15, July 15 and October 15 of each year, commencing on October 15, 2018, and to, and including, July 15, 2021.
Unless earlier converted, each share of the Series B Mandatory Convertible Preferred Stock will automatically convert on the second business day immediately following the last trading day of the settlement period into between 0.7326 and 0.8791 shares of our common stock, subject to anti-dilution adjustments. The number of shares of our common stock issuable on conversion of the Series B Mandatory Convertible Preferred Stock will be determined based on the average VWAP (as defined herein) per share of our common stock over the 20 consecutive trading day period beginning on and including the 21st scheduled trading day immediately preceding July 15, 2021, which we refer to as the “settlement period.” At any time prior to July 15, 2021, holders may elect to convert each share of the Series B Mandatory Convertible Preferred Stock into shares of our common stock at the minimum conversion rate of 0.7326 shares of our common stock per share of the Series B Mandatory Convertible Preferred Stock, subject to anti-dilution adjustments;provided,however, that if holders elect to convert any shares of the Series B Mandatory Convertible Preferred Stock during a specified period beginning on the effective date of a fundamental change (as defined herein), such shares of the Series B Mandatory Convertible Preferred Stock will be converted into shares of our common stock at the fundamental change conversion rate (as defined herein), and the holders will also be entitled to receive a fundamental change dividend make-whole amount and accumulated dividend amount (each as defined herein).
Concurrently with this offering, we are offering (the “Concurrent Offering”) 9,750,000 shares of our common stock pursuant to forward sale agreements we expect to enter into with the forward purchasers identified in the prospectus supplement for the Concurrent Offering. The Concurrent Offering is being made by means of a separate prospectus supplement and not by means of this prospectus supplement. The completion of this offering is not contingent on completion of the Concurrent Offering, and the completion of the Concurrent Offering is not contingent on the completion of this offering.
We intend to use the net proceeds we receive from this offering and pursuant to the forward sale agreements we plan to enter into in connection with the Concurrent Offering, if completed, to repay outstanding commercial paper, to fund working capital and for other general corporate purposes. See “Summary Information��� and “Use of Proceeds.”
Prior to this offering, there has been no public market for the Series B Mandatory Convertible Preferred Stock. We intend to apply to have the Series B Mandatory Convertible Preferred Stock listed on the New York Stock Exchange under the symbol “SREPRB.” Our common stock is listed on the New York Stock Exchange under the symbol “SRE.” On July 10, 2018, the last reported sale price of our common stock on the New York Stock Exchange was $117.30 per share.
Investing in the Series B Mandatory Convertible Preferred Stock involves risks. See the “Risk Factors” section on pageS-25 of this prospectus supplement.
| | | | | | | | |
| | Per Share | | | Total | |
Public Offering Price | | $ | 100.00 | | | $ | 500,000,000 | |
Underwriting Discount | | $ | 1.65 | | | $ | 8,250,000 | |
Proceeds to Sempra Energy (before expenses) | | $ | 98.35 | | | $ | 491,750,000 | |
We have granted the underwriters the option, exercisable in whole or from time to time in part, to purchase up to an additional 750,000 shares of our Series B Mandatory Convertible Preferred Stock from us solely to cover over-allotments, if any, at the public offering price per share shown above, less the underwriting discount and subject to possible adjustment as described under “Underwriting (Conflicts of Interest),” exercisable for 30 days after the date of this prospectus supplement.
Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The underwriters expect to deliver the Series B Mandatory Convertible Preferred Stock to purchasers on or about July 13, 2018.
Joint Book-Running Managers
| | | | |
Citigroup | | | | J.P. Morgan |
BofA Merrill Lynch | | Credit Suisse | | Deutsche Bank Securities |
Goldman Sachs & Co. LLC | | Wells Fargo Securities |
SeniorCo-Managers
| | | | |
BNP PARIBAS | | Credit Agricole CIB | | Mizuho Securities |
MUFG | | | | UBS Investment Bank |
July 10, 2018